铯-131近距离放疗治疗脑肿瘤的安全性与疗效
本研究回顾性分析了2010至2021年在纽约长老会/威尔康奈尔医学中心接受 resection 联合辅助铯-131近距离放疗的119例中枢神经系统肿瘤患者,评估总生存和局部控制。脑转移瘤、胶质瘤和脑膜瘤的1年生存率分别为53.3%、45.9%和73.3%,1年局部控制率分别为84.7%、34.1%和83.3%(p<0.001)。放射性坏死发生率为8.4%,伤口并发症发生率为11.8%。
要点
- 铯-131近距离放疗后脑转移瘤和脑膜瘤的1年局部控制率分别为84.7%和83.3%,胶质瘤为34.1%。
- 非小细胞肺癌脑转移瘤的局部控制率优于其他病理类型(90.8% vs 76.5%,p=0.039)。
- 放射性坏死发生率8.4%,且与较小肿瘤中位尺寸相关(2.4 cm vs 3.1 cm,p=0.034)。
核心结论
- 铯-131近距离放疗表现出良好的安全性和疗效特征,对所有治疗的病理类型均有较高的局部控制率。
研究设计与样本
- 回顾性综述,纳入2010至2021年在纽约长老会/威尔康奈尔医学中心接受切除联合辅助铯-131近距离放疗的所有中枢神经系统肿瘤患者,共119例。
主要发现
- 中位随访时间11.8个月(IQR 4.7-23.6),平均随访时间22.3±30.3个月。
- 1年生存率:脑转移瘤53.3%(95%CI 41.9-64.6%),胶质瘤45.9%(95%CI 24.8-67.0%),脑膜瘤73.3%(95%CI 50.9-95.7%)。
- 1年局部控制率:脑转移瘤84.7%,胶质瘤34.1%,脑膜瘤83.3%(p<0.001)。
- 脑转移瘤中,非小细胞肺癌的局部控制率优于其他病理类型(90.8% vs 76.5%,p=0.039)。
- 放射性坏死10例(8.4%),与较小中位肿瘤尺寸相关(2.4 cm [IQR 1.8-2.7] vs 3.1 cm [IQR 2.4-3.8],p=0.034);伤口并发症14例(11.8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of Cesium-131 (Cs-131) as a radiation source has led to a resurgence of brachytherapy for central nervous system (CNS) tumors. The aim of this study was to evaluate the safety and efficacy of the largest cohort of Cs-131 patients to-date. METHODS: A retrospective review of all CNS tumors treated with resection and adjuvant Cs-131 brachytherapy at New York-Presbyterian/Weill Cornell from 2010 to 2021 was performed. Overall survival (OS) and local control (LC) were assessed with Kaplan-Meier methodology. Univariable analysis was conducted to identify patient factors associated with local recurrence or radiation necrosis. RESULTS: Adjuvant Cs-131 brachytherapy following resection was performed in 119 patients with a median follow-up time of 11.8 (IQR 4.7-23.6) months and a mean of 22.3 +/-30.3 months. 1-year survival rates were 53.3% (95%CI 41.9-64.6%) for brain metastases (BrM), 45.9% (95%CI 24.8-67.0%) for gliomas, and 73.3% (95%CI 50.9-95.7%) for meningiomas. 1-year local control rates were 84.7% for BrM, 34.1% for gliomas, and 83.3% for meningiomas (p < 0.001). For BrM, local control was superior in NSCLC relative to other BrM pathologies (90.8% versus 76.5%, p = 0.039). Radiographic radiation necrosis (RN) was identified in 10 (8.4%) cases and demonstrated an association with smaller median tumor size (2.4 [IQR 1.8-2.7 cm] versus 3.1 [IQR 2.4-3.8 cm], p = 0.034). Wound complications occurred in 14 (11.8%) patients. CONCLUSIONS: Cs-131 brachytherapy demonstrated a favorable safety and efficacy profile characterized by high rates of local control for all treated pathologies. The concept of brachytherapy has seen a resurgence given the excellent results when Cs-131 is used as a source.
引用
- Bander ED, Kelly A, Ma X, et al. Safety and efficacy of Cesium-131 brachytherapy for brain tumors. J Neurooncol. 2023. PMID: 37249824. doi:10.1007/s11060-023-04352-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。